Quantcast

Latest Cisplatin Stories

da9126d890b38d451756da92445705ec1
2008-11-20 09:11:42

Agents bind to different targets than conventional drugs A new class of compounds called phosphaplatins can effectively kill ovarian, testicular, head and neck cancer cells with potentially less toxicity than conventional drugs, according to a new study published this week in the journal Proceedings of the National Academy of Sciences. The compounds could be less harmful than current cancer treatments on the market such as cisplatin and carboplatin because they don't penetrate the cell...

2008-11-14 09:00:34

CALGARY, Nov. 14 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that a poster presentation authored by Dr. Anders Kolb of the Nemours Center for Childhood Cancer Research entitled "Systemic Administration of REOLYSIN Inhibits Growth of Human Sarcoma Xenografts Alone and in Combination with Cisplatin and Radiation" is scheduled to be presented today at the 14th Annual Meeting of the Connective Tissue Oncology Society (CTOS). The meeting is being...

2008-10-02 12:06:58

Alimta has received US approval for use as a first-line therapy in locally advanced and metastatic non-small cell lung cancer in combination with cisplatin. This third FDA approval for Alimta follows its prominent use in patients with non-squamous carcinoma cell histology and highlights the shift towards a more tailored approach for lung cancer therapy. Alimta (pemetrexed) received US approval as a first-line therapy for locally advanced and metastatic non-small cell lung cancer (NSCLC)...

2008-09-30 09:45:00

Eli Lilly and Company has received approval from the FDA for the use of Alimta in combination with cisplatin, in the first-line treatment of locally-advanced and metastatic non-small cell lung cancer, for patients with nonsquamous histology. This marks the third US indication for Alimta. In 2004, Alimta has received consecutive approvals: first in combination with cisplatin as a treatment for patients with malignant pleural mesothelioma, whose disease is unresectable or who are otherwise not...

2008-09-29 09:00:14

INDIANAPOLIS, Sept. 29 /PRNewswire-FirstCall/ -- Eli Lilly and Company announced today it received approval from the U.S. Food and Drug Administration (FDA) for the use of ALIMTA(R) (pemetrexed for injection), in combination with cisplatin, in the first-line treatment of locally-advanced and metastatic non-small cell lung cancer (NSCLC), for patients with nonsquamous histology. ALIMTA is not indicated for treatment of patients with squamous cell non-small cell lung cancer. NSCLC is the...

2008-08-29 00:00:36

U.S. researchers say they have linked a genetic variant of a protein to resistance to the chemotherapy drug cisplatin. The University of California, San Diego, researchers found that when a specific variant form of PMS2 -- a cell repair protein that fixes DNA mistakes and plays a role in cell death -- is active, cisplatin doesn't kill cancer cells the way it normally does. In experiments using mouse cells, the researchers, led by Jean Wang and Richard Kolodner, found PMS2 normally...

2008-08-07 18:01:53

SEATTLE, Aug. 7 /PRNewswire/ -- Sound Pharmaceuticals (SPI) has received FDA notification that it may proceed with its Phase II study to prevent chemotherapy induced hearing loss. The Ph-II study will enroll 80 patients with advanced head and neck, and non-small cell lung cancer at the National Center for Rehabilitative Auditory Research at the Veterans Administration Hospital and the Oregon Health and Science University in Portland, Oregon. Hearing loss due to ototoxic medications such...

2008-07-17 09:00:19

SAN ANTONIO, July 17 /PRNewswire/ -- BioNumerik Pharmaceuticals, Inc. ("BioNumerik") today announced that patients with adenocarcinoma (the most frequently occurring form of lung cancer) participating in a Phase II clinical trial of Tavocept(TM) showed a survival increase of approximately 198 days (6.5 months). The trial observations included an approximate 40% reduction in mortality for adenocarcinoma patients receiving Tavocept. The percentage of adenocarcinoma patients in the Tavocept...

2008-06-24 02:30:28

U.S. medical scientists say they've found a compound that effectively treats colorectal cancer but with fewer side effects than with a commonly used drug. The newly investigated compound, known as cDPCP, is an analogue of cisplatin, a potent anticancer agent. The study found cDPCP might better target colorectal cells, potentially sparing other body tissues from damage, said Massachusetts Institute of Technology researchers. This compound, the antitumor properties of which were established...

2008-06-20 00:00:06

Canopus BioPharma: Len Rothstein, 818-980-5008 Fax. 818-980-5088 President len@canopusbiopharma.com or Investor Relations: Darrow Associates, Inc. Jordan Darrow, 631-367-1866 Fax. 631-614-3612 jdarrow@darrowir.com Canopus BioPharma, Inc. (OTC: CBIA), has confirmed the efficacy of its oncology candidate, CB1400, as a tumor reducing agent and has also demonstrated the synergistic effect of this drug in combination with both cisplatin and cetuximab (Erbitux) in two mice...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related